TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01396161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157 or Placebo
Description: One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157 or Placebo
Description: One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157 or Placebo
Description: One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157 or Placebo
Description: One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule twice daily for 14 days, immediately before breakfast and dinner, in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157 or Placebo
Description: One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once (or twice) daily for 14 days, immediately before breakfast (and dinner), in patients with type 2 diabetes.
Study: NCT00997672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00597727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peanut SLIT
Description: Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.

Intervention type: DRUG
Group type: OTHER
Intervention: Peanut SLIT
Description: Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.

Intervention type: DRUG
Group type: OTHER
Intervention: Peanut SLIT
Description: Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.

Intervention type: DRUG
Group type: OTHER
Intervention: Peanut SLIT
Description: Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SLIT
Description: Liquid glycerin without peanut which are dosed under the tongue.
Study: NCT02658500

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant Formula
Study: NCT00836641

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: prevenar
Description: 7-valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: prevenar
Description: 7-valent pneumococcal conjugate vaccine
Study: NCT00725868

Intervention type: OTHER
Group type: OTHER
Intervention: Data private hospitals, angioplasty, sampling of blood
Description: * Data private hospitals : Age, sex, index of body mass, factors of cardiovascular risk, medical surgical histories, treatment before and after the angioplasty, the renal insufficiency~* coronary angioplasty~* Sampling of blood : Before the angioplasty, 6 hours after the angioplasty and 24 hours after the angioplasty. A numeration of the proparents circulants (hématopoietics, PEC) and a numeration of CEC are made
Study: NCT00824200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: Multicomponent Behavioral and Exercise Therapy (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene \& non-pharmacological management of peripheral edema.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral
Description: Multicomponent Behavioral and Exercise Therapy (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene \& non-pharmacological management of peripheral edema.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin (alpha-adrenergic antagonist medication)
Description: 0.4 mg given daily
Study: NCT02658500

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: breast milk
Study: NCT00836641

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumovax
Description: 23 valent pneumococcal polysaccharide vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumovax
Description: 23 valent pneumococcal polysaccharide vaccine
Study: NCT02632227

Intervention type: PROCEDURE
Intervention: TFU(transfontanel ultrasound)
Description: The respiratory variation of the carotid artery blood flow peak velocity was measured using TFU before and after the fluid administration (10ml/kg for 20 min.)
Study: NCT00817258

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Description: Cisplatin 40mg/m2,weekly

Intervention type: RADIATION
Group type: OTHER
Intervention: 3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)
Description: 3D-CRT or IMRT
Study: NCT00824200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin (alpha-adrenergic antagonist medication)
Description: 0.4 mg given daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: tamsulosin placebo

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo behavioral intervention
Study: NCT01057316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formula PTX Stent - Dose 1
Description: Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formula PTX Stent - Dose 2
Description: Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
Study: NCT03054935

Intervention type: OTHER
Intervention: Indirect Calorimetry
Description: Measurement of resting energy expenditure
Study: NCT02836704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution~Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution~Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Pharmaceutical form: table or capsule~Route of administration: oral administration
Study: NCT03356002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Scan System
Description: Each subject will ingest the capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-Scan System
Description: Each subject will ingest the capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure
Study: NCT02836704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Pharmaceutical form: table or capsule~Route of administration: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acarbose
Description: Pharmaceutical form: table or capsule~Route of administration: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acarbose
Description: Pharmaceutical form: table or capsule~Route of administration: oral administration
Study: NCT02313077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-filo
Description: One 0.5 mL intramuscular (IM) injection of 1E8 (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1 (Groups 1 and 2), or on Day 29 (Group 3), or on Day 57 (Group 4), or on Day 15 (Group 5).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-filo
Description: One 0.5 mL intramuscular (IM) injection of 1E8 (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1 (Groups 1 and 2), or on Day 29 (Group 3), or on Day 57 (Group 4), or on Day 15 (Group 5).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-filo
Description: One 0.5 mL intramuscular (IM) injection of 1E8 (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1 (Groups 1 and 2), or on Day 29 (Group 3), or on Day 57 (Group 4), or on Day 15 (Group 5).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26. ZEBOV
Description: One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1 (Groups 3, 4 and 5), or on Day 29 (Group 1), or on Day 57 (Group 2).
Study: NCT03111498

Intervention type: OTHER
Group type: OTHER
Intervention: practice-based training programme (one-to-one teaching)
Description: practice-based training programme (one-to-one teaching) for conducting VAD
Study: NCT02313077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26. ZEBOV
Description: One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1 (Groups 3, 4 and 5), or on Day 29 (Group 1), or on Day 57 (Group 2).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26. ZEBOV
Description: One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1 (Groups 3, 4 and 5), or on Day 29 (Group 1), or on Day 57 (Group 2).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26. ZEBOV
Description: One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1 (Groups 3, 4 and 5), or on Day 29 (Group 1), or on Day 57 (Group 2).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26. ZEBOV
Description: One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1 (Groups 3, 4 and 5), or on Day 29 (Group 1), or on Day 57 (Group 2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 (Groups 1 and 3), or on Day 1 and 57 (Groups 2 and 4).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 (Groups 1 and 3), or on Day 1 and 57 (Groups 2 and 4).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 (Groups 1 and 3), or on Day 1 and 57 (Groups 2 and 4).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 (Groups 1 and 3), or on Day 1 and 57 (Groups 2 and 4).
Study: NCT03214198

Intervention type: DRUG
Intervention: Vonoprazan
Description: Vonoprazan tablets
Study: NCT01080209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimo PS DDS®
Description: Patients who received Brimo PS DDS® intravitreal implant in a previous study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimo PS DDS®
Description: Patients who received Brimo PS DDS® intravitreal implant in a previous study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimo PS DDS®
Description: Patients who received Brimo PS DDS® intravitreal implant in a previous study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimo PS DDS®
Description: Patients who received Brimo PS DDS® intravitreal implant in a previous study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimo PS DDS®
Description: Patients who received Brimo PS DDS® intravitreal implant in a previous study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimo PS DDS®
Description: Patients who received Brimo PS DDS® intravitreal implant in a previous study.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Patients who recieved sham in a previous study.
Study: NCT01558245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tissue kallikrein
Description: Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
Study: NCT01544153

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WEB
Description: Usual services available through www.BecomeAnEX.org, a publicly available, evidence-based smoking cessation website.
Study: NCT01544153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WEB
Description: Usual services available through www.BecomeAnEX.org, a publicly available, evidence-based smoking cessation website.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WEB
Description: Usual services available through www.BecomeAnEX.org, a publicly available, evidence-based smoking cessation website.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WEB
Description: Usual services available through www.BecomeAnEX.org, a publicly available, evidence-based smoking cessation website.
Study: NCT02583607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brava
Description: The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.~woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it.
Study: NCT02465710

Intervention type: PROCEDURE
Intervention: Pelvic organ prolapse surgery without mesh
Description: retrospective study

Intervention type: PROCEDURE
Intervention: Pelvic organ prolapse surgery with mesh
Study: NCT01544153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network
Description: Proactive communications from established members of the community (Integrators) designed to integrate study participants into the online social network on BecomeAnEX.org.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network
Description: Proactive communications from established members of the community (Integrators) designed to integrate study participants into the online social network on BecomeAnEX.org.
Study: NCT02696018

Intervention type: DEVICE
Intervention: Ultrasonography
Description: Ultrasonographic assessment of the diaphragm function
Study: NCT01544153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: A free 4-week supply of nicotine replacement therapy (patch, gum, or lozenge), provided as an over-the-counter product, meaning that no additional support or guidance will be provided to parallel the experience subjects would have if they purchased NRT on their own.
Study: NCT03111498

Intervention type: OTHER
Group type: OTHER
Intervention: theory-based training programme
Description: theory-based training programme for conducting VAD
Study: NCT01621750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel Tablets 300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel Tablets 300 mg
Study: NCT06019104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented training
Description: Task-oriented training is defined as an approach based on movement science and motor learning, where the patient makes functional movements specific to a certain task and receives feedback. Task-oriented training focuses on improving performance on functional tasks through targeted practice and repetition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Gaze stabilization exercises included head-fixed right-left eye movements, head-fixed up-down eye movements, eye fixed right-left head movements, and eye fixed up-down head movements.
Study: NCT02341300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cast Iron Pot
Description: Cast iron pot

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Alumnium Pot
Description: Aluminum Skillet
Study: NCT01798550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Twice daily dosing
Study: NCT03640793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Implantation of 6 PPIS implants
Study: NCT03879252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: Brushing teeth three times a day (extra-soft toothbrush) with a 1.4% baking mouthwash solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwashes
Description: Mouthwashes three times a day with a 1.4% baking mouthwash solution.
Study: NCT00683371

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Specimen collection
Description: 10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Specimen collection
Description: 10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
Study: NCT01636778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-497115-GR
Description: TPO receptor agonist to increase platelet count
Study: NCT02074865

Intervention type: BIOLOGICAL
Intervention: biological samples
Study: NCT04685434

Intervention type: OTHER
Intervention: Shriners Hospital for Children Upper Extremity Evaluation
Description: The interventions are evaluating tools for the functional performance of the upper extremity.
Study: NCT01798550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Twice daily dosing
Study: NCT02541253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3110A
Description: A single 0.5mL dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GCFLU Pre-filled Syringe inj.
Description: A single 0.5mL dose intramuscular injection
Study: NCT01024387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Study: NCT03650881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neutrogena ® Light Therapy Acne Mask (MASK)
Description: Daily use of the OTC Neutrogena Light Therapy Acne Mask once daily for 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical OTC benzoyl peroxide 2.5% gel and OTC adapalene
Description: Daily treatment with Reference Therapy OTC topical generic benzoyl peroxide 2.5% gel in the morning and OTC generic adapalene 0.1% gel at night
Study: NCT01908777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin
Study: NCT01988818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex® Border Post-Op
Description: wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard wound dressing
Description: standard wound dressing after hip-knee or spinal surgery
Study: NCT02384148

Intervention type: OTHER
Intervention: Circadian rhythm measurement

Intervention type: OTHER
Intervention: Circadian rhythm measurement

Intervention type: OTHER
Intervention: Circadian rhythm measurement

Intervention type: OTHER
Intervention: Circadian rhythm measurement

Intervention type: PROCEDURE
Intervention: Skin biopsy
Description: A 2mm diameter skin biopsy is performed by a physician using standard procedure.

Intervention type: PROCEDURE
Intervention: Skin biopsy
Description: A 2mm diameter skin biopsy is performed by a physician using standard procedure.

Intervention type: PROCEDURE
Intervention: Skin biopsy
Description: A 2mm diameter skin biopsy is performed by a physician using standard procedure.

Intervention type: PROCEDURE
Intervention: Skin biopsy
Description: A 2mm diameter skin biopsy is performed by a physician using standard procedure.
Study: NCT04369027

Intervention type: DIAGNOSTIC_TEST
Intervention: passive leg raising
Description: passive leg raising: to raise the legs of the patients by adjusting the angle of the patient's bed during one minute.~Tidal volume challenge: an increas by 2ml/Kg of the tidal volume during one minute
Study: NCT03986645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR data acquisition
Description: MR data acquisition using CE and non-CE marked pulse sequences.
Study: NCT03843268

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMPS Gondola
Description: Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS); the treatment requires less than 2 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AMPS Gondola
Description: Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS); the treatment requires less than 2 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Gondola
Description: The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Gondola
Description: The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger